Business
VivoSim Expands Asia-Pacific Access to NAMKind™ Human-Based Toxicology Services Through New Distributor Agreement in Korea and China
JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevanceSAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in
About this update from Vivosim Labs, Inc.
[{"type":"image","alt":"VivoSim Labs, Inc.","displaySize":"","headline":null,"caption":"VivoSim Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":133,"url":"https://media.zenfs.com/en/globenewswire.com/e54b5ed2b47b2a40c4e408056374d68a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3k1uNndpaNI76.ORZ8sOyw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e54b5ed2b47b2a40c4e408056374d68a","width":300,"height":133}},"lazy":false},{"type":"text","content":"JCBio appointed for Korea; Tekon Biotech appointed for China provide access to liver and small-intestine NAM screening with “molecules in, data out” speed and human relevance","length":174,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim Labs”), a provider of next-generation New Approach Methodologies (NAMs) for preclinical safety, today announced it has signed JCBio as an authorized distributor in Korea and Tekon Biotech as an authorized distributor in China for its NAMKind™ toxicology services in liver and small intestine. The appointments expand VivoSim’s commercial presence across Asia-Pacific, which potentially provides faster access to human-relevant toxicology services for pharmaceutical and biotechnology organizations facing growing pressure to de-risk programs earlier and accelerate timelines.","length":681,"tagName":"p"},{"type":"text","content":"A market inflection point: global demand for New Approach Methodologies (NAMs) is accelerating","length":94,"tagName":"p"},{"type":"text","content":"Across the industry, the demand for human-relevant, fit-for-purpose toxicology is rising sharply as drug developers seek earlier readouts, clearer translation to clinical outcomes, and meaningful reductions in late-stage attrition. VivoSim’s NAMKind™ services are designed to meet that demand with a simple, scalable model: “molecules in, data out”—supporting small molecules, biologics, and advanced modalities—and delivering actionable results with a targeted 30-day turnaround time per compound.","length":498,"tagName":"p"},{"type":"text","content":"Korea’s regulatory direction aligns with U.S. FDA momentum on NAM adoption","length":74,"tagName":"p"},{"type":"text","content":"Korea’s Ministry of Food and Drug Safety (M...